Thu, 19 Nov 2026
Pharma in Focus

Connecting you with your industry every day

Featured

And the 2026 PRIME winners are...

Three companies were the biggest winners at last night's PRIME awards ceremony, each celebrating three wins. Find out who took home a gong...

Industry & Companies

Pfizer warns of looming threat to pharmas

The company's biggest competitor will not be "Lilly or AstraZeneca" but a far fiercer rival, the CEO says, and all Big Pharmas will have to lift their game

Government & Policy

'What's the point?' MA calls out Govt plan

Industry body says reports the Federal Government might freeze the PBS co-pay carries little weight if the drugs patients need don't come to Australia

Industry & Companies

Has Novo pulled a trump card on Lilly?

The neck-and-neck battle to be the first to the Australia market with an oral GLP-1 drug for weight loss has hit fever pitch with Novo unveiling a launch date

More News
Regulatory & Reimbursement

Third broad listing submitted to the PBAC

The PBAC will consider 19 changes to listings next March, including some big new indications and another multi-cancer reimbursement submission

Regulatory & Reimbursement

PBAC kicks off 2027 with 43 submissions

On the super-sized list for the March 2027 meeting are 13 drugs and two vaccines vying to secure a recommendation to win government subsidy for the first time

Earlier News
Featured

Lilly pips rival in Aussie obesity pill race

Two weeks after Novo's obesity pill won TGA approval, Lilly seems to have stolen first-to-market advantage after securing registration for its rival treatment yesterday, promising to launch in "days"

Government & Policy

Access gap stymies Aussie ambition

Australia has the smarts to become a regional leader in the cell & gene therapy space, but a dismal patient access record is thwarting the industry's ambition

Industry & Companies

Inside private internet conversations about your drugs

A new tool gives pharma visibility across the entire digital information ecosystem, detailing what doctors and patients are privately asking about a company's drugs - and their competitor's - as well as what they're being told

Pipeline & Intellectual Property

Watch out... J&J buys into lucrative market

$5B acquisition puts J&J head-to-head with both Bayer and Roche with a "potentially transformative" drug that could redefine patient care

Regulatory & Reimbursement

What shook up the Top PBS Earners List?

There have been changes to the Top 10 PBS Drugs List with a couple of treatments taking a tumble while most others have soared

Industry & Companies

Zeller makes another industry move

New membership marks yet another sign that this pharma is quickly cementing itself in Australia's biopharmaceutical industry

Regulatory & Reimbursement

No, No, No: PBAC justifies three rejections

The drugs work and get ticks overseas, but Australia's inflexible reimbursement system means three medicines addressing unmet need, were knocked back

All positions →

Jobs

  1. Senior Pharmacovigilance Associate - 12 month New

    HPGSydneyClinical
  2. General Manager - Primary Health New

    HPGMelbourneClinical
  3. Clinical Project Manager | Oncology or Early Phase Trials New

    HPGSydneyClinical
  4. Clinical Project Manager New

    HPGSydneyClinical
  5. External Engagement Lead New

    HPGMelbourneAccess
  6. External Engagement Lead New

    HPGSydneyAccess
  7. Therapeutic Area Specialist New

    HPGSydneySales
  8. Territory Manager New

    HPGPerthSales
More News
Pipeline & Intellectual Property

Keytruda challenger hits a speed hump

The FDA has declined to approve Summit's highly-anticipated challenger to the world's biggest drug, but analysts are branding the decision "very much a one-off"

Industry & Companies

Second time lucky for pharma buy-out?

Mayne Pharma is on the block again, with a new suitor eager to buy the company in a deal worth more than $600M but without its Australian business

Featured

Aussie pharma juggles the generation gap

One of the most age diverse workforces in history is seeing Boomers, Gen X, Millennials and Gen Z working side-by-side but communication style is one of the biggest sticking points

Other News
Featured

Who will bag the last PBS listings of 2026?

Twelve pharmas are jostline to score the last PBS listings for the year, from brand new drugs to new indications, with two companies vying to win two additions

Industry & Companies

Pharma celebrates 25 years in Australia

After opening its Australian operations in 2001 with just four full-time employees, this pharma now has a 67-strong workforce

Sales, Marketing & Public Relations

The best oncology drug launch in history?

A monster return after just five weeks on the market has led one analyst to dub the launch of this cancer drug, the GOAT

Regulatory & Reimbursement

Bayer, Besins Healthcare add new drugs

The TGA has approved a new treatment for contraception and endometriosis plus a new contrast agent for enhanced diagnostic imaging

Earlier News
Jobs & Workplace

Inside Aussie pharma's kindest workplace

Recently recertified as a Kind Company this company reveals how its ANZ team is embedding kindness into its everyday culture and beyond

Awards

Pharmacists name favourite pharma

This pharma has picked up the prestigious Most Preferred Supplier gong at the Self-Care Excellence Awards but another company scored the highest number of recognitions, with four wins

Industry & Companies

Drug shortages to persist into 2027

Shortages of some hormone replacement therapy patches are expected to continue well into 2027 after sponsors provided the TGA with an updated outlook for supply

In Case You Missed It
Regulation & Legal

TGA cracks down on fake Lilly drug

The regulator has raised fresh concerns about fakes of Lilly's experimental weight loss drug, homing in on a specific branded counterfeit

Industry & Companies

Vertex staff roll up their sleeves

For the 18th year running Vertex has undertaken its Global Week of Service with the Aussie team pitching in on a home improvement project

More News